查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2006238

骨癌治疗市场：2026-2032年全球市场预测（按治疗方法、癌症类型、患者年龄和最终用户划分）

Bone Cancer Treatment Market by Treatment Type, Cancer Type, Patient Age, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，骨癌治疗市场价值将达到 61.1 亿美元，到 2026 年将成长至 71.3 亿美元，到 2032 年将达到 177.1 亿美元，复合年增长率为 16.40%。

主要市场统计数据
基准年 2025 61.1亿美元
预计年份：2026年 71.3亿美元
预测年份 2032 177.1亿美元
复合年增长率 (%) 16.40%

一份面向管理阶层的骨癌治疗发展历程总结报告。报告重点关注临床创新、相关人员的优先事项以及可用于策略规划的实用建议。

骨癌治疗处于临床复杂性和快速治疗方法创新交汇点，这给临床医生、保险公司和整个行业带来了不断变化的优先事项。免疫疗法和标靶治疗的最新进展正在改变临床预期，而影像学、外科技术和支持性护理的进步也在不断改善患者的治疗路径。同时，相关人员对真实世界证据、价值证明和整合式照护模式的需求，正在改变治疗方法的研发、核准和实施方式。

探索模式转移，这种转变将重塑骨癌治疗，其驱动力是免疫肿瘤学、精准医学、医疗设备和不断发展的医疗保健服务模式的突破。

骨癌治疗格局已发生翻天覆地的变化，这主要得益于科学突破、监管进步和新型医疗服务模式的推动。免疫肿瘤学已从概念验证迈向在某些骨癌中积极开展临床应用，激发了人们对过继性细胞疗法、癌症疫苗和查核点抑制剂的广泛关注。同时，标靶治疗的研发也突飞猛进，血管生成抑制剂、单株抗体和蛋白酪氨酸激酶抑制剂等药物凭藉其多样化的作用机制，为传统的细胞毒性疗法提供了补充。

对 2025 年前影响美国骨癌治疗的供应链累积关税压力和政策应对措施进行详细评估。

美国在2025年前累积征收的关税为骨癌治疗生态系统带来了多层次的供应链和成本管理挑战。关税导致药品成分、生物製药和专用医疗设备的价格上涨，推高了医院、专科诊所和癌症中心的采购成本，促使它们重新评估筹资策略和库存管理。为此，许多相关人员正在加快供应商多元化，并探索近岸外包和回流生产等倡议，以减轻跨境政策变化的影响。

从综合细分的观点，明确了治疗方法的定义，包括临床路径、癌症亚型、分销管道、终端用户趋势和患者年龄层。

精细化的细分方法阐明了个别治疗方法和给药选择如何影响临床路径和运作重点。根据治疗类型，整体情况包括化疗、冷冻疗法、免疫疗法、放射疗法、放射线治疗和标靶治疗。其中，化疗进一步细分为烷化剂、抗代谢药物、植物生物碱和含铂类药物。化疗则透过过继性细胞疗法、癌症疫苗和免疫查核点抑制剂进行更详细的探讨，而标靶治疗则细分为血管生成抑制剂、单株抗体和蛋白酪氨酸激酶抑制剂。这些治疗层面的区分会影响临床试验设计、伴随诊断的需求以及医疗服务提供者所需的服务能力。

决定美洲、欧洲、中东和非洲以及亚太地区准入途径和临床引入的区域趋势，以及它们对供应和合作的影响。

受法律规范、支付系统、临床基础设施和当地生产能力的影响，区域差异仍然是骨癌治疗药物取得、引进和治疗策略的主要决定因素。儘管美洲地区先进的肿瘤中心和活跃的临床研究支持新治疗方法的快速引进，但公立和私人医疗机构在药物取得方面仍然存在差距。过渡政策以及与支付方的谈判正在影响新药和服务模式的引进方式，这需要与医疗技术评估机构和综合医疗网络进行有针对性的合作。

竞争和企业资料揭示了领先的生物製药和医疗设备开发公司如何调整其产品线、生产和伙伴关係关係，以加速骨癌治疗。

主要企业和机构正在采取差异化策略，以应对骨癌治疗药物研发和商业化的复杂挑战。一些生物製药公司优先发展标靶治疗和免疫肿瘤学项目，以实现产品线多元化；而另一些公司则投资于生物製药、联合治疗和伴随诊断，以增强临床差异化优势。医疗设备和外科技术公司正在根据外科医生和患者的需求调整产品开发，以增强保肢手术和术中影像能力，并改善功能性预后。

为产业领导者提供可操作的、高优先顺序的行动方案，以优化骨癌管理的研发、商业化、供应链弹性和以病人为中心的服务。

产业领导者应优先考虑一系列切实可行的措施，以平衡短期业务永续营运与长期临床和商业性定位。首先，透过供应商多元化、认证替代製造地以及与主要供应商签订联合采购协议，增强供应链韧性，确保关键治疗方法和医疗设备的持续供应。其次，透过整合前瞻性的真实世界资料收集，加快核准后研究的证据产生；并与供应商网路合作，展示疗效比较和病患报告结果，以支持报销谈判。

严谨的调查方法解释了资料来源、相关人员参与、证据检验验证和品管，这些构成了治疗环境分析的基础。

本分析基于一种混合调查方法，该方法结合了与关键相关人员的互动、对二手证据的严格整合以及数据三角验证，以确保其可靠性和有效性。主要资讯来源包括对临床医生、医院药剂师、保险公司代表和行业高管的结构化检验，以了解实际部署挑战、临床决策因素和采购考虑。这些定性研究结果透过对同侪审查的临床文献、监管文件和公共公告的针对性审查得到系统性补充，从而将临床疗效、安全性概况和政策趋势置于更广泛的背景中进行分析。

综合考虑临床、商业性和政策因素，提供全面的见解，以指导整个骨癌治疗生态系统的策略决策。

本报告提出的综合分析将临床进展、营运挑战和政策趋势连结起来，从而对骨癌治疗的未来发展前景做出统一展望。包括标靶治疗和免疫肿瘤学方法在内的新型治疗方法正在拓展治疗选择，并为联合治疗有望增强疗效的持久性。同时，供应链的限制、不断变化的报销模式以及法规结构的区域差异，都要求制定前瞻性的策略规划，以将科学预期转化为患者获益。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 骨癌治疗市场：依治疗方法

  • 化疗
    • 烷化剂
    • 抗代谢物
    • 植物生物碱
    • 铂製剂
  • 冷冻疗法
  • 免疫疗法
    • 过继性细胞疗法
    • 癌症疫苗
    • 查核点抑制剂
  • 放射线治疗
  • 外科手术
  • 标靶治疗
    • 血管新生抑制剂
    • 单株抗体
    • 蛋白酪氨酸激酶抑制剂

第九章 骨癌治疗市场：依癌症类型划分

  • 软骨肉瘤
  • 伊文氏肉瘤
  • 骨癌

第十章 骨癌治疗市场：依患者年龄划分

  • 成人版
  • 老年人
  • 儿童

第十一章 骨癌治疗市场：依最终用户划分

  • 癌症中心
  • 医院
    • 私立医院
    • 公立医院
  • 专科诊所
    • 肿瘤诊所
    • 整形外科诊所

第十二章 骨癌治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 骨癌治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 骨癌治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国：骨癌治疗市场

第十六章 中国：骨癌治疗市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cellectar Biosciences, Inc.
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Ipsen SA
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-B1685377A111

The Bone Cancer Treatment Market was valued at USD 6.11 billion in 2025 and is projected to grow to USD 7.13 billion in 2026, with a CAGR of 16.40%, reaching USD 17.71 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.11 billion
Estimated Year [2026] USD 7.13 billion
Forecast Year [2032] USD 17.71 billion
CAGR (%) 16.40%

A focused executive framing of bone cancer treatment evolution highlighting clinical innovations, stakeholder priorities, and actionable insights for strategic planning

Bone cancer treatment sits at the intersection of high clinical complexity and rapid therapeutic innovation, creating a dynamic set of priorities for clinicians, payers, and industry. Recent advances in immunotherapy and targeted agents have shifted clinical expectations while improvements in imaging, surgical techniques, and supportive care continue to refine patient pathways. Concurrently, stakeholder demands for real-world evidence, value demonstration, and integrated care models are altering how therapies are developed, approved, and adopted.

Against this backdrop, a strategic executive summary must highlight not only the scientific progress but also the operational and policy realities that determine patient access. Emerging trends such as combination regimens, adaptive trial designs, and companion diagnostics are reshaping clinical decisions. Meanwhile, healthcare providers and systems are balancing cost pressures with a growing imperative to deliver personalized, outcomes-driven care. This introduction frames the subsequent analysis by outlining the clinical innovations, regulatory and reimbursement considerations, and stakeholder behaviors that together define the contemporary landscape for bone cancer treatment.

An exploration of paradigm shifts reshaping bone cancer care driven by immuno-oncology breakthroughs, precision therapeutics, devices, and evolving care delivery models

The landscape of bone cancer therapy has undergone transformative shifts driven by scientific breakthroughs, regulatory evolution, and new models of care delivery. Immuno-oncology has moved from proof-of-concept to active clinical integration in select bone sarcomas, catalyzing broader interest in adoptive cell therapies, cancer vaccines, and checkpoint inhibitors. Targeted therapy development has accelerated in parallel, with angiogenesis inhibitors, monoclonal antibodies, and tyrosine kinase inhibitors providing mechanistic alternatives that complement classical cytotoxic approaches.

In tandem, advances in surgical techniques and radiotherapy modalities, including precision delivery and dose optimization, have expanded options for limb-preserving interventions and improved quality-of-life outcomes. Commercially, there is a pronounced shift toward value-based contracting, outcomes-based evidence generation, and closer alignment between manufacturers and provider systems to de-risk adoption. Technology-enabled care pathways, remote monitoring, and telehealth are improving continuity for patients across treatment cycles, while real-world evidence is increasingly used to refine indications, dosing strategies, and comparative effectiveness assessments. Collectively, these shifts are redefining clinical paradigms and creating a more complex but opportunity-rich environment for developers, clinicians, and health systems.

A detailed assessment of cumulative tariff-driven supply chain pressures and policy responses influencing access to bone cancer therapies in the United States through 2025

The cumulative imposition of tariffs in the United States through 2025 has introduced a layered set of supply chain and cost-management challenges for the bone cancer treatment ecosystem. Tariff-related increases on pharmaceutical components, biologic inputs, and specialized medical devices can elevate procurement costs for hospitals, specialty clinics, and cancer centers, prompting a re-evaluation of sourcing strategies and inventory management. In response, many stakeholders have accelerated supplier diversification efforts and explored nearshoring or reshoring initiatives to reduce exposure to cross-border policy volatility.

Beyond direct cost implications, tariffs can affect clinical access timelines when manufacturers adjust logistics, shift production schedules, or prioritize markets based on pricing and reimbursement dynamics. These shifts have reinforced the importance of robust supplier qualification, long-term contracting, and transparent cost modeling between manufacturers and institutional buyers. Payers and policymakers have also become more prominent voices in discussions about affordability and access, prompting novel reimbursement arrangements and targeted patient assistance programs. Ultimately, the tariff environment has highlighted the interdependence of trade policy, manufacturing resilience, and patient access, underscoring the need for coordinated risk mitigation and policy engagement strategies among industry participants.

Integrated segmentation perspective revealing treatment modalities, cancer subtypes, distribution channels, end-user dynamics, and patient age cohorts that define clinical pathways

A granular segmentation approach clarifies how distinct therapeutic and delivery choices shape clinical pathways and operational priorities. Based on treatment type, the landscape encompasses Chemotherapy, Cryotherapy, Immunotherapy, Radiotherapy, Surgery, and Targeted Therapy, with chemotherapy further delineated into Alkylating Agents, Antimetabolites, Plant Alkaloids, and Platinum Compounds; immunotherapy further examined through Adoptive Cell Therapy, Cancer Vaccines, and Checkpoint Inhibitors; and targeted therapy subdivided into Angiogenesis Inhibitors, Monoclonal Antibodies, and Tyrosine Kinase Inhibitors. These treatment-level distinctions influence clinical trial design, companion diagnostic needs, and service line capabilities required by providers.

When considering cancer type, differentiation across Chondrosarcoma, Ewing Sarcoma, and Osteosarcoma reveals unique biological behaviors, age distributions, and therapeutic sensitivities that dictate distinct clinical programs and patient management strategies. Distribution channel segmentation identifies Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy pathways, with online channels further characterized by Ecommerce Platforms and Manufacturer Websites, each requiring tailored logistics, cold chain integrity, and digital engagement strategies. End-user segmentation captures Cancer Centers, Hospitals, and Specialty Clinics, with hospitals further classified as Private and Public and specialty clinics including Oncology and Orthopedic Clinics, highlighting the diversity in procurement cycles, clinical capabilities, and payer interactions. Finally, patient age cohorts of Adult, Geriatric, and Pediatric necessitate differentiated dosing, safety monitoring, and psychosocial support frameworks that must be embedded into any treatment deployment plan.

Regional dynamics that determine access pathways and clinical adoption across Americas, Europe Middle East & Africa, and Asia-Pacific with implications for supply and collaboration

Regional variation continues to be a major determinant of access, adoption, and therapeutic strategy for bone cancer treatment, influenced by regulatory frameworks, payer systems, clinical infrastructure, and local manufacturing capabilities. In the Americas, advanced oncology centers and significant clinical research activity support rapid adoption of novel therapies, yet disparities in access persist across public and private care settings. Transitional policies and payer negotiations shape how new agents and service models are implemented, requiring targeted engagement with health technology assessment bodies and integrated delivery networks.

Within Europe, Middle East & Africa, regulatory diversity and heterogeneity in reimbursement create a mosaic of adoption timelines, with pockets of rapid innovation in major European health systems and ongoing access challenges in several Middle Eastern and African markets. Collaborative public-private initiatives and regional manufacturing investments are emerging responses to these gaps. In Asia-Pacific, a mix of large patient populations, growing clinical trial capacity, and increasing domestic biopharmaceutical capabilities is accelerating localized development and commercialization pathways, while differences in regulatory stringency and pricing policies continue to necessitate region-specific strategies. Across all regions, cross-border partnerships, knowledge transfer, and targeted capacity building are critical to improving equitable access and operational resilience.

Competitive and corporate intelligence revealing how leading biopharma and device developers are aligning pipelines, manufacturing, and partnerships to accelerate bone cancer care

Leading companies and institutions are pursuing differentiated strategies to navigate the complexities of bone cancer therapy development and commercialization. Some biopharmaceutical players are prioritizing pipeline diversification through targeted therapy and immuno-oncology programs, while others are investing in biologics, combination regimens, and companion diagnostics to strengthen clinical differentiation. Device and surgical technology firms are enhancing limb-sparing procedures and intraoperative imaging capabilities, aligning product development with surgeon and patient needs to improve functional outcomes.

At the corporate level, partnerships between biotech innovators and established pharmaceutical manufacturers are accelerating late-stage development and scaling of manufacturing capacity. Contract research organizations and specialized contract manufacturers are playing pivotal roles in enabling rapid clinical growth and maintaining supply continuity. Meanwhile, provider organizations and integrated health systems are forming collaborative arrangements with industry to pilot value-based payment models and real-world evidence programs. These competitive and cooperative behaviors highlight a landscape where alignment across R&D, manufacturing, payer engagement, and provider adoption determines long-term success, and where agility in strategic execution remains a core differentiator.

Practical, prioritized actions for industry leaders to optimize R&D, commercialization, supply resilience, and patient-centric services in bone cancer management

Industry leaders should prioritize a set of actionable moves that balance near-term operational resilience with longer-term clinical and commercial positioning. First, strengthen supply chain resilience by diversifying suppliers, qualifying secondary manufacturing sites, and engaging in collaborative procurement arrangements with major providers to ensure continuity of critical therapies and devices. Second, accelerate evidence generation by integrating prospective real-world data collection into post-approval studies and partnering with provider networks to demonstrate comparative effectiveness and patient-reported outcomes that support reimbursement negotiations.

Third, invest in regulatory and health technology assessment engagement early in development to align endpoints, safety strategies, and health economic evidence generation with payer expectations. Fourth, design patient-centric delivery models that address logistical burdens, including expanded outpatient infusion capacity, digital monitoring for adherence and toxicity surveillance, and tailored support programs for pediatric and geriatric populations. Fifth, pursue strategic alliances that enable rapid scale-up of manufacturing and distribution, and consider outcome-based contracting structures where appropriate to share risk with payers and providers. By implementing these steps, organizations can improve access, reduce adoption friction, and strengthen the value proposition of novel bone cancer therapies.

Rigorous research methodology explaining data sources, stakeholder engagements, evidence triangulation, and quality controls underpinning the treatment landscape analysis

This analysis is grounded in a hybrid research methodology that combines primary stakeholder engagement with rigorous secondary evidence synthesis and data triangulation to ensure reliability and relevance. Primary inputs included structured interviews with clinicians, hospital pharmacists, payer representatives, and industry executives to capture real-world implementation challenges, clinical decision drivers, and procurement considerations. These qualitative insights were systematically complemented by a targeted review of peer-reviewed clinical literature, regulatory documents, and public policy pronouncements to contextualize clinical effectiveness, safety profiles, and policy trends.

Quantitative validation was achieved through analysis of clinical trial registries, prescription utilization patterns, and published epidemiologic data where available, followed by cross-validation against provider and manufacturer disclosures. Throughout the process, iterative expert review cycles were used to reconcile discrepancies and refine interpretations, while governance procedures ensured methodological transparency, reproducibility, and ethical handling of confidential information. The resulting evidence base emphasizes triangulated insights that reflect both the scientific trajectory and the operational realities that drive therapy adoption and patient outcomes.

Summative insights that consolidate clinical, commercial, and policy considerations to guide strategic decision-making across the bone cancer treatment ecosystem

The synthesis presented herein brings together clinical advancements, operational imperatives, and policy dynamics to provide a coherent perspective on the future of bone cancer treatment. Novel therapeutic modalities, including targeted agents and immuno-oncology approaches, are expanding therapeutic options and creating new avenues for combination strategies that may enhance response durability. At the same time, supply chain pressures, evolving reimbursement models, and regional heterogeneity in regulatory frameworks require proactive strategic planning to translate scientific promise into patient benefit.

Looking ahead, stakeholders that integrate robust evidence generation, supply resilience, and patient-centered service design will be best positioned to accelerate adoption and improve outcomes. Cross-sector collaboration, from joint R&D ventures to outcome-based commercial agreements, offers viable pathways to manage risk and enhance access. In summary, coordinated action across clinical development, manufacturing, policy engagement, and provider partnerships will be essential to realize the full potential of emerging therapies while addressing affordability and equity concerns.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bone Cancer Treatment Market, by Treatment Type

  • 8.1. Chemotherapy
    • 8.1.1. Alkylating Agents
    • 8.1.2. Antimetabolites
    • 8.1.3. Plant Alkaloids
    • 8.1.4. Platinum Compounds
  • 8.2. Cryotherapy
  • 8.3. Immunotherapy
    • 8.3.1. Adoptive Cell Therapy
    • 8.3.2. Cancer Vaccines
    • 8.3.3. Checkpoint Inhibitors
  • 8.4. Radiotherapy
  • 8.5. Surgery
  • 8.6. Targeted Therapy
    • 8.6.1. Angiogenesis Inhibitors
    • 8.6.2. Monoclonal Antibodies
    • 8.6.3. Tyrosine Kinase Inhibitors

9. Bone Cancer Treatment Market, by Cancer Type

  • 9.1. Chondrosarcoma
  • 9.2. Ewing Sarcoma
  • 9.3. Osteosarcoma

10. Bone Cancer Treatment Market, by Patient Age

  • 10.1. Adult
  • 10.2. Geriatric
  • 10.3. Pediatric

11. Bone Cancer Treatment Market, by End User

  • 11.1. Cancer Centers
  • 11.2. Hospitals
    • 11.2.1. Private Hospitals
    • 11.2.2. Public Hospitals
  • 11.3. Specialty Clinics
    • 11.3.1. Oncology Clinics
    • 11.3.2. Orthopedic Clinics

12. Bone Cancer Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Bone Cancer Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Bone Cancer Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Bone Cancer Treatment Market

16. China Bone Cancer Treatment Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Amgen Inc.
  • 17.7. AstraZeneca PLC
  • 17.8. Bayer AG
  • 17.9. Bristol-Myers Squibb Company
  • 17.10. Cellectar Biosciences, Inc.
  • 17.11. Daiichi Sankyo Company, Limited
  • 17.12. Eisai Co., Ltd.
  • 17.13. Eli Lilly and Company
  • 17.14. F. Hoffmann-La Roche Ltd
  • 17.15. Gilead Sciences, Inc.
  • 17.16. GlaxoSmithKline plc
  • 17.17. Ipsen S.A.
  • 17.18. Johnson & Johnson Services, Inc.
  • 17.19. Merck & Co., Inc.
  • 17.20. Novartis AG
  • 17.21. Pfizer Inc.
  • 17.22. Sanofi S.A.
  • 17.23. Takeda Pharmaceutical Company Limited
  • 17.24. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BONE CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BONE CANCER TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BONE CANCER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY PATIENT AGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BONE CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BONE CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BONE CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY PLANT ALKALOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY PLANT ALKALOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY PLANT ALKALOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY PLATINUM COMPOUNDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY PLATINUM COMPOUNDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY CRYOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY CRYOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY CRYOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY CHONDROSARCOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY CHONDROSARCOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY CHONDROSARCOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY EWING SARCOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY EWING SARCOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY EWING SARCOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY OSTEOSARCOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY OSTEOSARCOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY OSTEOSARCOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY CANCER CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY CANCER CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY ONCOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY ONCOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY ORTHOPEDIC CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY ORTHOPEDIC CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY ORTHOPEDIC CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS BONE CANCER TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS BONE CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS BONE CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS BONE CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS BONE CANCER TREATMENT MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS BONE CANCER TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS BONE CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS BONE CANCER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS BONE CANCER TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA BONE CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA BONE CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA BONE CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA BONE CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA BONE CANCER TREATMENT MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA BONE CANCER TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA BONE CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA BONE CANCER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA BONE CANCER TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA BONE CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA BONE CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA BONE CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA BONE CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA BONE CANCER TREATMENT MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA BONE CANCER TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA BONE CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA BONE CANCER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA BONE CANCER TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA BONE CANCER TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA BONE CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA BONE CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA BONE CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA BONE CANCER TREATMENT MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA BONE CANCER TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA BONE CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA BONE CANCER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA BONE CANCER TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE BONE CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE BONE CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE BONE CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE BONE CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE BONE CANCER TREATMENT MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE BONE CANCER TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE BONE CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE BONE CANCER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE BONE CANCER TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST BONE CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST BONE CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST BONE CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST BONE CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST BONE CANCER TREATMENT MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST BONE CANCER TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST BONE CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST BONE CANCER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST BONE CANCER TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA BONE CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA BONE CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA BONE CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA BONE CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA BONE CANCER TREATMENT MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA BONE CANCER TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA BONE CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA BONE CANCER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA BONE CANCER TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC BONE CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC BONE CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC BONE CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC BONE CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC BONE CANCER TREATMENT MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC BONE CANCER TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC BONE CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC BONE CANCER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC BONE CANCER TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN BONE CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN BONE CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN BONE CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN BONE CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN BONE CANCER TREATMENT MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN BONE CANCER TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN BONE CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN BONE CANCER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN BONE CANCER TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 190. GCC BONE CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. GCC BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. GCC BONE CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 193. GCC BONE CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 194. GCC BONE CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. GCC BONE CANCER TREATMENT MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. GCC BONE CANCER TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 197. GCC BONE CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. GCC BONE CANCER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 199. GCC BONE CANCER TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION BONE CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION BONE CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION BONE CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION BONE CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION BONE CANCER TREATMENT MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION BONE CANCER TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION BONE CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION BONE CANCER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION BONE CANCER TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS BONE CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS BONE CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS BONE CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS BONE CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS BONE CANCER TREATMENT MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS BONE CANCER TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS BONE CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS BONE CANCER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS BONE CANCER TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 220. G7 BONE CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. G7 BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. G7 BONE CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 223. G7 BONE CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 224. G7 BONE CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 225. G7 BONE CANCER TREATMENT MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. G7 BONE CANCER TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 227. G7 BONE CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. G7 BONE CANCER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 229. G7 BONE CANCER TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 230. NATO BONE CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. NATO BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. NATO BONE CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 233. NATO BONE CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 234. NATO BONE CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 235. NATO BONE CANCER TREATMENT MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. NATO BONE CANCER TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 237. NATO BONE CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. NATO BONE CANCER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 239. NATO BONE CANCER TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES BONE CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES BONE CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES BONE CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES BONE CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES BONE CANCER TREATMENT MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES BONE CANCER TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES BONE CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES BONE CANCER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES BONE CANCER TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA BONE CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA BONE CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA BONE CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA BONE CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA BONE CANCER TREATMENT MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA BONE CANCER TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA BONE CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA BONE CANCER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA BONE CANCER TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)